ProfileGDS5678 / 1446100_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 6% 5% 5% 4% 4% 5% 5% 5% 5% 5% 5% 5% 5% 5% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.117626
GSM967853U87-EV human glioblastoma xenograft - Control 22.058475
GSM967854U87-EV human glioblastoma xenograft - Control 32.057725
GSM967855U87-EV human glioblastoma xenograft - Control 41.995094
GSM967856U87-EV human glioblastoma xenograft - Control 52.00174
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.100695
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.074575
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.039425
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.036555
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.054715
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.045255
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.035775
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.044345
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.048865